FDA 483 - Immunex Rhode Island Corporation - December 07, 2021

Immunex Rhode Island Corporation, a drug substance manufacturer in West Greenwich, Rhode Island, was cited for several deficiencies during an FDA inspection. Observations included a lack of procedural control for incoming material qualification, inadequate cleaning procedures, poorly maintained facility equipment, and insufficient standard operating procedures. These issues indicate a need for improved quality control and operational oversight.